Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Applied Materials reports 3 months of fiscal year 2023

2/17/23 AMAT

The AbbVie announced a quarterly dividend

2/16/23 ABBV

Samolet intends to bring the service Samolet Plus to IPO by 2025

2/16/23 SMLT

NRG Energy reports for 2022

2/16/23 NRG

Government will give Gazprom Neft a refundable tax deduction at 9% per annum

2/16/23 SIBN

Paramount in 2022 to quadruple in size

2/16/23 PARA

Severstal plans to increase sales by 7% in 2023

2/16/23 CHMF

Russneft increased oil and condensate production in 2022

2/16/23 RNFT

Yandex Market began crediting its sellers

2/16/23 YNDX

RussNeft reported for 2022 according to RAS

2/16/23 RNFT